pfizer glp-1 news Phase IIb Data Support Monthly Dosing for Obesity China Opens Its Weight-Loss Drug

In contrast to these results, a study using nationwide registry data from Sweden, Denmark, and Norwayinvolving 121,254 new GLP-1 RA users and 185,027 new SGLT-2 inhibitor users documented 557 intestinal obstruction events, with no significant correlation between GLP-1 RA use and increased intestinal obstruction risk, thereby refuting earlier safety concerns [12]

Vilsboll T, Agerso H, Krarup T, and Holst JJ

Approval for treatment is not guaranteed

The Journal of Clinical Endocrinology and Metabolism

Many people report committing to a long-term plan without meaning to and find they cannot cancel their plan once they have signed up

(17) Semaglutide was found to enhance bone formation through the upregulation of osteogenic pathways- specifically -catenin via the Wnt signaling pathway